Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > PRAC recommendations on safety signals

https://www.ema.europa.eu/documents/prac-recommendation/prac-recommendations-signals-adopted-7-10-february-2022-prac-meeting_en.pdf

Philippe Calandra 18 March 2022 All news
  • ← Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 March 2022
  • EMA Management Board: highlights of March 2022 meeting →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26-29 September 2022
  • Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022
  • MedDRA : whatsnew ?
Copyright © 2018 - Pharmya - Legal terms - Quality Policy